高级搜索
人脑胶质瘤中Smad-1、Smad-2和Smad-4的表达及意义[J]. 肿瘤防治研究, 2014, 41(01): 22-26. DOI: 10.3971/j.issn.1000-8578.2014.01.006
引用本文: 人脑胶质瘤中Smad-1、Smad-2和Smad-4的表达及意义[J]. 肿瘤防治研究, 2014, 41(01): 22-26. DOI: 10.3971/j.issn.1000-8578.2014.01.006
Expression and Signifi cance of Smad-1, Smad-2 and Smad-4 in Human Glioma[J]. Cancer Research on Prevention and Treatment, 2014, 41(01): 22-26. DOI: 10.3971/j.issn.1000-8578.2014.01.006
Citation: Expression and Signifi cance of Smad-1, Smad-2 and Smad-4 in Human Glioma[J]. Cancer Research on Prevention and Treatment, 2014, 41(01): 22-26. DOI: 10.3971/j.issn.1000-8578.2014.01.006

人脑胶质瘤中Smad-1、Smad-2和Smad-4的表达及意义

Expression and Signifi cance of Smad-1, Smad-2 and Smad-4 in Human Glioma

  • 摘要: 目的 检测BMPs/BMPR/Smads信号转导通路上的人脑胶质瘤组织中Smad-1、Smad-2、Smad-4的表达,探讨其在人脑胶质瘤发生发展中的作用及其与临床病理分级的关系。方法 分别应用RT-PCR技术和免疫组织化学SABC法检测20例正常脑组织和40例不同级别人脑胶质瘤组织中Smad-1、Smad-2、Smad-4 mRNA和蛋白质表达量,并分析其与患者的年龄、性别、病理分级的相关性。结果 人脑胶质瘤组织Smad-1、Smad-2、Smad-4 mRNA表达量比正常脑组织显著降低(0.277±0.125 vs. 0.573±0.097,P<0.01;0.282±0.111 vs. 0.613±0.105,P<0.01;0.389±0.101 vs. 0.483±0.098,P<0.05),且Ⅲ+Ⅳ组显著低于Ⅰ+Ⅱ组(0.250±0.106 vs. 0.327±0.119,P<0.05;0.2451±0.109 vs. 0.315±0.113,P<0.05;0.347±0.121 vs. 0.434±0.102,P<0.05)。蛋白质表达的阳性率显著低于正常脑组织(37.50% vs. 75.00%,P<0.0 1;20.00% vs. 65.00%,P<0.01; 25.00% vs. 70.00%,P<0.01),且Ⅲ+Ⅳ组显著低于Ⅰ+Ⅱ组(16.67% vs. 54.55%,P<0.05;5.56% vs. 31.82%, P<0.05;5.56% vs. 40.91%,P<0.05)。上述指标的变化与患者的年龄及性别无关。结论 Smad-1、Smad-2、Smad-4 在人脑胶质瘤中的表达水平与胶质瘤的发生发展和恶性程度密切相关,提示Smad-1、Smad-2、Smad-4 可能参与胶质瘤发生发展过程。

     

    Abstract: Objective To detect the expressions of Smad-1,Smad-2 and Smad-4 of BMPs/BMPR/Smads signaling transduction pathway in human brain glioma, to research their role of them in tumorigenesis and progression of brain glioma and their correlation with clinical pathology. Methods The mRNA and protein expressions of Smad-1,Smad-2 and Smad-4 were detected in 20 normal brain tissues and 40 samples with human glioma by RT-PCR and SABC immunohistochemical methods, respectively, and analyzed the correlation with the patient's age, gender and pathological grade. Results Compared with normal brain tissues, Smad-1,Smad-2 and Smad-4 mRNA expressions in human glioma were reduced signifi cantly(0.277 ±0.125 vs. 0.573±0.097, P<0.01;0.282±0.111 vs. 0.613±0.105, P<0.01;0.389±0.101 vs. 0.483± 0.098,P<0.05 )especially in Ⅲ and Ⅳ stage tumor tissues(0.250±0.106 vs. 0.327±0.119,P<0.05;0.2451±0.109 vs. 0.315±0.113,P<0.05;0.347±0.121 vs. 0.434±0.102,P<0.05),and protein expressions in human glioma were reduced significantly(37.50% vs. 75.00% , P<0.0 1;20.00% vs. 65.00%,P<0.01;25.00% vs. 70.00%,P<0.01)especially in Ⅲ and Ⅳ stage tumor tissues(16.67% vs. 54.55%,P<0.05;5.56% vs. 31.82%,P<0.05;5.56% vs. 40.91%,P<0.05). The difference was not related with the patient's age and gender. Conclusion Expressions of Smad-1,Smad-2 and Smad-4 in human glioma are closely related with glioma malignant degree. It prompts Smad-1, Smad-2 and Smad-4 participate in brain glioma occurrence and development process.

     

/

返回文章
返回